| abstract |
A molecular crystal form of (S)-3-(2,5-dimethyl-6-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)piperidin- 1 -yl)pyrimidin-4-ylamino)-2-(4- methoxyphenylsulfonamido)propanoic acid is characterized by an X-ray powder diffraction ("XRPD") spectrum that comprises peaks at 2θ angles of 7.44, 14.80, 16.64, and 23.04 ±0.2°. The molecular crystal can be formulated into pharmaceutical composition for treating or controlling diseases resulting from pathological angiogenesis. |